Overview


According to FutureWise analysis the market for alpha thalassemia is expected to register a CAGR of 10.70% from 2023-2031 .

FutureWise Market Research has instantiated a report that provides an intricate analysis of Alpha Thalassemia Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Alpha Thalassemia Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
  • Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Calimmune Inc
  • CRISPR Therapeutics
  • Editas Medicine Inc
  • Errant Gene Therapeutics LLC
  • Gamida Cell Ltd
  • Gilead Sciences Inc
  • Incyte Corp
  • Ionis Pharmaceuticals Inc
  • IRBM Science Park SpA
  • Johnson and Johnson
  • Kiadis Pharma NV
  • La Jolla Pharmaceutical Company
  • Merck and Co Inc
  • PharmaEssentia Corp
  • Protagonist Therapeutics Inc
  • Sangamo Therapeutics Inc
  • Zydus Cadila Healthcare Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Hb Bart syndrome
  • HbH disease
  • Silent Carrier State
  • Trait

By Diagnosis

  • Perinatal Testing
    • Complete Blood Count (CBC)
    • DNA testing
  • Prenatal Testing
    • Prenatal Genetic Testing
    • Chorionic Villus Sampling
  • Pre-Implantation

By Treatment

  • Blood Transfusions
  • Iron Chelation
  • Bone Marrow
  • Stem Cell Transplant
  • Surgery
  • Gene Therapy

By End-User

  • Hospitals
  • Biotechnological laboratories
  • Diagnostic Laboratories
  • Educational Research Institutes
  • Pharmaceutical Industries
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Alpha Thalassemia Market By Type, By Diagnosis, By Treatment, By End-User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping-Type launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Alpha Thalassemia Market Variables, Trends and Scope

    •          1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Treatment Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Alpha Thalassemia Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Alpha Thalassemia Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Treatment Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Treatment Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Alpha Thalassemia Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hb Bart syndrome
        2. HbH disease
        3. Silent Carrier State
        4. Trait

  • 8.   Global Alpha Thalassemia Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Perinatal Testing
         1.1. Blood Count (CBC)
         1.2. DNA testing
        2. Prenatal Testing
         2.1. Prenatal Genetic Testing
         2.2. Chorionic Villus Sampling
        3. Pre-Implantation

  • 9.   Global Alpha Thalassemia Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Blood Transfusions
        2. Iron Chelation
        3. Bone Marrow
        4. Stem Cell Transplant
        5. Surgery and
        6. Gene Therapy

  • 10.   Global Alpha Thalassemia Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospitals,
        2. Biotechnological laboratories
        3. Diagnostic Laboratories
        4. Educational Research Institutes
        5. Pharmaceutical Industries
        6. Others

  • 11.   North America Alpha Thalassemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Alpha Thalassemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Alpha Thalassemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Alpha Thalassemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Types Offered and Financial Layouts)

    •   1. Pharmaceuticals Inc
         1.1. Company Overview
         1.2. Type Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Alnylam Pharmaceuticals Inc
         2.1. Company Overview
         2.2. Type Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Calimmune Inc
         3.1. Company Overview
         3.2. Type Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. PathoFinder BV
         4.1. Company Overview
         4.2. Type Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Editas Medicine Inc
         5.1. Company Overview
         5.2. Type Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Errant Gene Therapeutics LLC
         6.1. Company Overview
         6.2. Type Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Gamida Cell Ltd
         7.1. Company Overview
         7.2. Type Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Gilead Sciences Inc
         8.1. Company Overview
         8.2. Type Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Incyte Corp
         9.1. Company Overview
         9.2. Type Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Ionis Pharmaceuticals Inc
         10.1. Company Overview
         10.2. Type Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. IRBM Science Park SpA
         11.1. Company Overview
         11.2. Type Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Johnson and Johnson
         12.1. Company Overview
         12.2. Type Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Kiadis Pharma NV
         13.1. Company Overview
         13.2. Type Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. La Jolla Pharmaceutical Company
         14.1. Company Overview
         14.2. Type Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Merck and Co Inc
         15.1. Company Overview
         15.2. Type Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. PharmaEssentia Corp
         16.1. Company Overview
         16.2. Type Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Protagonist Therapeutics Inc
         17.1. Company Overview
         17.2. Type Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Sangamo Therapeutics Inc
         18.1. Company Overview
         18.2. Type Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Zydus Cadila Healthcare Ltd.
         19.1. Company Overview
         19.2. Type Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11